LLY

988.57

+2.13%↑

JNJ

225.57

+0.63%↑

ABBV

206.03

-1.03%↓

UNH

363.82

-1.87%↓

AZN

181.33

-1.06%↓

LLY

988.57

+2.13%↑

JNJ

225.57

+0.63%↑

ABBV

206.03

-1.03%↓

UNH

363.82

-1.87%↓

AZN

181.33

-1.06%↓

LLY

988.57

+2.13%↑

JNJ

225.57

+0.63%↑

ABBV

206.03

-1.03%↓

UNH

363.82

-1.87%↓

AZN

181.33

-1.06%↓

LLY

988.57

+2.13%↑

JNJ

225.57

+0.63%↑

ABBV

206.03

-1.03%↓

UNH

363.82

-1.87%↓

AZN

181.33

-1.06%↓

LLY

988.57

+2.13%↑

JNJ

225.57

+0.63%↑

ABBV

206.03

-1.03%↓

UNH

363.82

-1.87%↓

AZN

181.33

-1.06%↓

Home・Akciju saraksts・Incyte Corp

Incyte Corp

Slēgts

SektorsVeselības aprūpe

97.54 0.46

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

96.18

Max

97.69

Galvenie mērījumi
By Trading Economics
Ienākumi	4.1M 303M
Pārdošana	-234M 1.3B
P/E Sektora vidējais	13.682 49.8
EPS	1.81
Peļņas marža	23.834
Darbinieki	2,844
EBITDA	-47M 367M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt
Prognoze 12 mēnešiem	+11.24% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 28. jūl.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	358M 19B
Iepriekšējā atvēršanas cena	97.08
Iepriekšējā slēgšanas cena	97.54

Ziņu noskaņojums

By Acuity

25%

75%

92 / 347 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Bullish Evidence

59.52 / 62.66 Atbalsts un pretestība

Incyte Corp Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 5. maijs 23:43 UTC

Galvenie ziņu notikumi

New Zealand's Unemployment Rate Falls in 1Q

2026. g. 5. maijs 23:20 UTC

Karstas akcijas

Stocks to Watch: AMD, Super Micro, Arista Networks, Freshworks

2026. g. 5. maijs 21:48 UTC

Peļņas

Suncor Energy Reports Higher 1Q Profit on Increased Oil Production

2026. g. 5. maijs 21:05 UTC

Iegādes, apvienošanās, pārņemšana

Canada Antitrust Watchdog Seeks to Kibosh Keyera Deal for Plains' Canada Gas Business -- 4th Update

2026. g. 6. maijs 00:00 UTC

Tirgus saruna

Canada Energy Minister Signals Energy Investments in the Pipeline -- Market Talk

2026. g. 5. maijs 23:39 UTC

Tirgus saruna

Gold Rises; Trump Pauses 'Project Freedom' to See if Iran Deal Can Be Finalized -- Market Talk

2026. g. 5. maijs 22:26 UTC

Tirgus saruna

AMD Data-Center Business Continues to Surge -- Market Talk

2026. g. 5. maijs 22:20 UTC

Tirgus saruna

AMD's AI Revolution is Still in Early Innings, Analysts Say -- Market Talk

2026. g. 5. maijs 22:08 UTC

Peļņas

Correction to "Palantir Beats Forecasts" on May 4. -- WSJ

2026. g. 5. maijs 22:07 UTC

Peļņas

AMD Stock Soars on Strong Earnings and Growing Confidence About AI -- Barrons.com

2026. g. 5. maijs 21:48 UTC

Peļņas

Pan American Silver 1Q Adj EPS $1.09 >PAAS

2026. g. 5. maijs 21:48 UTC

Peļņas

Pan American Silver 1Q Rev $1.2B >PAAS

2026. g. 5. maijs 21:42 UTC

Peļņas

Arista Networks Beats Expectations, Offers Upside Guidance. The Stock Is Down. -- Barrons.com

2026. g. 5. maijs 21:38 UTC

Peļņas

AMD Stock Jumps on Strong Earnings and Growing Confidence About AI -- Barrons.com

2026. g. 5. maijs 21:30 UTC

Peļņas

Arista Networks Beats Expectations, Offers Upside Guidance. The Stock Is Down. -- Barrons.com

2026. g. 5. maijs 21:29 UTC

Peļņas

AMD Stock Jumps on Strong Earnings and Growing Confidence About AI -- Barrons.com

2026. g. 5. maijs 21:26 UTC

Peļņas

Strategy Posts Wider Loss as Bitcoin Holdings Hit $64 Billion. The Stock Falls. -- Barrons.com

2026. g. 5. maijs 21:25 UTC

Peļņas

Alcon Inc. 1Q EPS 39c >ALC.EB

2026. g. 5. maijs 21:25 UTC

Peļņas

Alcon Inc. 1Q Rev $2.71B >ALC.EB

2026. g. 5. maijs 21:24 UTC

Peļņas

AMD Stock Jumps on Strong Earnings and Growing Confidence About AI -- Barrons.com

2026. g. 5. maijs 21:18 UTC

Peļņas

Mistras Backs 2026 Rev $730M-$750M >MG

2026. g. 5. maijs 21:17 UTC

Peļņas

AMD Stock Jumps on Solid Earnings. AI Continues to Drive Data Center Chips. -- Barrons.com

2026. g. 5. maijs 21:15 UTC

Peļņas

Strategy Records Loss of Nearly $13 Billion as Bitcoin Continues Decline -- WSJ

2026. g. 5. maijs 21:12 UTC

Peļņas

These Stocks Are Today's Movers: Intel, PayPal, Palantir, Shopify, Micron, Duolingo, and More -- Barrons.com

2026. g. 5. maijs 21:11 UTC

Peļņas

SSR Mining 1Q Rev $581.8M >SSRM

2026. g. 5. maijs 21:10 UTC

Peļņas

SSR Mining 1Q Adj EPS $1.15 >SSRM

2026. g. 5. maijs 21:10 UTC

Peļņas

SSR Mining 1Q EPS $1.16 >SSRM

2026. g. 5. maijs 21:08 UTC

Peļņas

Arista Networks Beats Expectations, Offers Upside Guidance. The Stock Is Down. -- Barrons.com

2026. g. 5. maijs 21:01 UTC

Peļņas

Intact Financial 1Q EPS C$4.12 >IFC.T

2026. g. 5. maijs 21:01 UTC

Karstas akcijas

Stocks to Watch Recap: Palantir, AMD, Intel, HSBC -- WSJ

Salīdzinājums

Cenas izmaiņa

Incyte Corp Prognoze

Cenas mērķis

By TipRanks

11.24% augšup

Prognoze 12 mēnešiem

Vidējais 108.06 USD 11.24%

Augstākais 135 USD

Zemākais 75 USD

Pamatojoties uz 19 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Incyte Corp — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

19 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 19 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Incyte Corp — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

59.52 / 62.66Atbalsts un pretestība

Bullish events outweigh bearish events.

All events are bearish.

Noskaņojums

By Acuity

92 / 347 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Incyte Corp

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation